General Update: Latest Advances in Hepatology

Nov 09 2025
Convention Center: Ballroom B, Level 3
2:00 PM - 3:30 PM

World Class Speakers

Vincent Chen, MD
Presenter

Vincent Chen, MD

University of Michigan Medical Center
Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD
Presenter

Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD

Indiana University School of Medicine
Michele M. Tana, MD, MHS
Moderator

Michele M. Tana, MD, MHS

University of California San Francisco

Description

Presenters offer a comprehensive exploration of 3 key areas in hepatology: MASH, alcohol-associated liver disease, and primary biliary cholangitis (PBC). Attendees learn how to optimize patient selection for MASH therapies by utilizing clinical and diagnostic criteria, distinguishing MASH from cirrhosis, and incorporating fibrosis assessment to guide treatment strategies. Speakers also address the complexities of managing alcohol-associated liver disease, focusing on early recognition, evidence-based interventions, and overcoming long-term care challenges. Finally, participants gain insights into the diagnosis and treatment of PBC, including the use of current therapies and effective monitoring strategies to enhance patient outcomes. 

Journey Maps

Presentations

2:00 PM - 2:25 PM
Nov 09 2025
Washington, D.C.

Optimizing Patient Selection for Metabolic Dysfunction-Associated Steatohepatitis Therapies: Identifying At-Risk Patients and Excluding Cirrhosis

Vincent Chen, MD, Presenter
ALD
MASLD
2:25 PM - 2:50 PM
Nov 09 2025
Washington, D.C.

Advances in the Management of Alcohol-Associated Liver Disease

Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD, Presenter
ALD
MASLD
2:50 PM - 3:15 PM
Nov 09 2025
Washington, D.C.

Comprehensive Care for Primary Biliary Cholangitis and Overlap: Diagnosis and Treatment Strategies

Michele M. Tana, MD, MHS, Presenter
ALD
MASLD

Objectives

  • Review how to identify patients with at-risk MASH using clinical and diagnostic criteria, and how to effectively distinguish MASH from cirrhosis.
  • Describe the role of fibrosis assessment in guiding MASH therapy.
  • List the clinical features and risk factors of alcohol-associated liver disease, and review evidence-based management strategies and long-term care challenges.
  • Summarize the diagnostic tools and criteria for primary biliary cholangitis (PBC).
  • Discuss PBC treatment options and their applications, and monitoring strategies for improving patient outcomes.
Chair

Mazen Noureddin, MD, MHSc

Houston Methodist Hospital